UCB4594

N/A

Report date: 2024/04/25 20:00:07

Base Information

Drug NameUCB4594

Drug Alias NameUCB4594UCB-4594

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody

Mechanisms of ActionHLA class I histocompatibility antigen, alpha chain G inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants

TargetsHLA class I histocompatibility antigen, alpha chain G

Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung +[12]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUcb Sa

China Registration ClassN/A

Develop Information

Active CompaniesUcb Biopharma Srl Ucb Sa Cancer Research UK

Inactive CompaniesN/A

Active IndicationsSolid tumoursUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung +[12]

Inactive IndicationsN/A

Other Information

ATC CodeN/A